Jacobus Pharmaceutical Company Inc., based in Plainsboro, New Jersey, is a pharmaceutical company that specializes in the production of medications. They recently issued a voluntary worldwide recall of their product, Ruzurgi amifampridine 10 mg tablets, due to contamination with yeast, mold, and bacterial organisms. The recall was prompted by laboratory test results that revealed the presence of these contaminants, which can potentially cause serious and life-threatening infections, particularly in individuals with underlying immunosuppressive conditions.
Ruzurgi amifampridine is used as a treatment for Lambert Eaton Syndrome (LEMS) in patients aged 6 to less than 17. The affected product was distributed globally to specialty pharmacies and physicians. Jacobus Pharmaceutical Company Inc. is taking immediate action to notify distributors and customers, and arrangements are being made for the return of all recalled products. Consumers who have purchased Ruzurgi amifampridine are advised to discontinue use and return the product to the company.
Generated from the website